Skip to main content

Advertisement

Table 5 Predictors of TSH normalization among hyperthyroid patients attending UoGCSH

From: Normalization of thyroid function tests among thyrotoxicosis patients attending a University Hospital in North-West Ethiopia

Variables   Univariate analysis Multivariate analysis
CHR (95% CI) p-value AHR (95% CI) p-value
Age (years)   0.987 [0.970–1.005] 0.151 0.967 [0.937–0.998] 0.036
Gender Female 0.992 [0.359–2.379] 0.988
Etiology GD 1   1  
TMNG 0.343 [0.141–0.836] 0.019 0.580 [0.147–2.287] 0.436
Toxic nodular goiter 0.415 [0.166–1.038] 0.060 0.872 [0.218–3.499] 0.847
Duration of symptoms before treatment (months)   0.998 [0.996–1.000] 0.141 1.000 [0.997–1.002] 0.708
WHO goiter size 0 1   1  
I 0.248 [0.030–2.024] 0.193
II 0.356 [0.047–2.676] 0.315
III 0.336 [0.042–2.692] 0.304
Baseline TSH   1.293 [0.891–1.874] 0.175 1.214 [0.647–2.279] 0.545
Baseline FT4   0.993 [0.990–0.996] 0.000 0.992 [0.988–0.997] 0.000
Baseline T3   0.907 [0.797–1.033] 0.142 0.966 [0.887–1.051] 0.418
PTU dose: initial   1.001 [0.999–1.004] 0.246 1.001 [0.999–1.004] 0.289
PTU dose: Maintenance   0.999 [0.995–1.004] 0.832 0.999 [0.994–1.004] 0.662
  1. AHR Adjusted Hazard Ratio, CHR Crude Hazard Ratio, CI Confidence Interval, GD Grave’s Disease, FT4 Free Thyroxine, PTU Propylthiouracil, T3 Triiodo thyronine, TMNG Toxic Multinodular Goiter, TFT Thyroid Function Tests, TSH Thyroid Stimulating Hormone, WHO World Health Organization